# A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study

> **NCT00192608** · NA · COMPLETED · sponsor: **Kirby Institute** · enrollment: 40 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** saquinavir 500 formulation
- **DRUG:** cross-over arm

## Key facts

- **NCT ID:** NCT00192608
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192608, "A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00192608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*